SE0301654D0 - Novel compounds - Google Patents

Novel compounds

Info

Publication number
SE0301654D0
SE0301654D0 SE0301654A SE0301654A SE0301654D0 SE 0301654 D0 SE0301654 D0 SE 0301654D0 SE 0301654 A SE0301654 A SE 0301654A SE 0301654 A SE0301654 A SE 0301654A SE 0301654 D0 SE0301654 D0 SE 0301654D0
Authority
SE
Sweden
Prior art keywords
novel compounds
pyridazine
therapy
triazine compounds
compounds
Prior art date
Application number
SE0301654A
Other languages
English (en)
Inventor
David Cheshire
Nicholas Kindon
Michael Stocks
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Priority to SE0301654A priority Critical patent/SE0301654D0/sv
Publication of SE0301654D0 publication Critical patent/SE0301654D0/sv
Priority to TW093114511A priority patent/TW200509935A/zh
Priority to JP2006508571A priority patent/JP2006526619A/ja
Priority to US10/559,202 priority patent/US20060189613A1/en
Priority to PCT/SE2004/000851 priority patent/WO2004108690A1/en
Priority to EP04735834A priority patent/EP1633723A1/en
Priority to UY28345A priority patent/UY28345A1/es
Priority to ARP040101942A priority patent/AR044613A1/es
Priority to SA04250149A priority patent/SA04250149A/ar

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/47—One nitrogen atom and one oxygen or sulfur atom, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
    • C07D237/06—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D237/10—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D237/20—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
    • C07D237/06—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D237/10—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D237/22—Nitrogen and oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/52—Two oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D253/00—Heterocyclic compounds containing six-membered rings having three nitrogen atoms as the only ring hetero atoms, not provided for by group C07D251/00
    • C07D253/02—Heterocyclic compounds containing six-membered rings having three nitrogen atoms as the only ring hetero atoms, not provided for by group C07D251/00 not condensed with other rings
    • C07D253/06—1,2,4-Triazines
    • C07D253/065—1,2,4-Triazines having three double bonds between ring members or between ring members and non-ring members
    • C07D253/07—1,2,4-Triazines having three double bonds between ring members or between ring members and non-ring members with hetero atoms, or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
SE0301654A 2003-06-05 2003-06-05 Novel compounds SE0301654D0 (sv)

Priority Applications (9)

Application Number Priority Date Filing Date Title
SE0301654A SE0301654D0 (sv) 2003-06-05 2003-06-05 Novel compounds
TW093114511A TW200509935A (en) 2003-06-05 2004-05-21 Novel compounds
JP2006508571A JP2006526619A (ja) 2003-06-05 2004-06-02 ケモカイン受容体活性（ｃｃｒ４）を調節するスルホンアミド化合物
US10/559,202 US20060189613A1 (en) 2003-06-05 2004-06-02 Sulphonamide Compounds that Modulate Chemokine Receptor Activity (CCR4)
PCT/SE2004/000851 WO2004108690A1 (en) 2003-06-05 2004-06-02 Sulphonamide compounds that modulate chemokine receptor activity (ccr4)
EP04735834A EP1633723A1 (en) 2003-06-05 2004-06-02 Sulphonamide compounds that modulate chemokine receptor activity (ccr4)
UY28345A UY28345A1 (es) 2003-06-05 2004-06-03 Compuestos novedosos
ARP040101942A AR044613A1 (es) 2003-06-05 2004-06-04 Heteroaril derivados de sulfonamidas como moduladores del receptor de quimioquina (ccr4)
SA04250149A SA04250149A (ar) 2003-06-05 2004-06-05 مركبات جديدة

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE0301654A SE0301654D0 (sv) 2003-06-05 2003-06-05 Novel compounds

Publications (1)

Publication Number Publication Date
SE0301654D0 true SE0301654D0 (sv) 2003-06-05

Family

ID=29212393

Family Applications (1)

Application Number Title Priority Date Filing Date
SE0301654A SE0301654D0 (sv) 2003-06-05 2003-06-05 Novel compounds

Country Status (9)

Country Link
US (1) US20060189613A1 (sv)
EP (1) EP1633723A1 (sv)
JP (1) JP2006526619A (sv)
AR (1) AR044613A1 (sv)
SA (1) SA04250149A (sv)
SE (1) SE0301654D0 (sv)
TW (1) TW200509935A (sv)
UY (1) UY28345A1 (sv)
WO (1) WO2004108690A1 (sv)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI328007B (en) 2002-01-16 2010-08-01 Astrazeneca Ab Novel compounds
SE0301650D0 (sv) * 2003-06-04 2003-06-04 Astrazeneca Ab Novel compounds
SE0301653D0 (sv) * 2003-06-05 2003-06-05 Astrazeneca Ab Novel compounds
EP1956009A1 (en) * 2005-12-02 2008-08-13 Mitsubishi Tanabe Pharma Corporation Aromatic compound
WO2007063934A1 (ja) * 2005-12-02 2007-06-07 Mitsubishi Tanabe Pharma Corporation 脂環式複素環化合物
TW200730512A (en) * 2005-12-12 2007-08-16 Astrazeneca Ab Novel compounds
WO2009151910A2 (en) * 2008-05-25 2009-12-17 Wyeth Combination product of receptor tyrosine kinase inhibitor and fatty acid synthase inhibitor for treating cancer
KR20160006717A (ko) * 2013-05-14 2016-01-19 액티브 바이오테크 에이비 S100-저해제로서 유용한 n-(헤테로아릴)-설폰아미드 유도체
TW201811766A (zh) * 2016-08-29 2018-04-01 瑞士商諾華公司 N-(吡啶-2-基)吡啶-磺醯胺衍生物及其用於疾病治療之用途
IL274444B1 (en) * 2017-11-06 2024-02-01 Rapt Therapeutics Inc Chemokine receptor modulators for the treatment of Epstein-Barr virus-positive cancer
MX2021006696A (es) 2018-12-06 2021-07-07 Daiichi Sankyo Co Ltd Derivado de cicloalcano-1,3-diamina.
WO2020161623A1 (en) * 2019-02-06 2020-08-13 Novartis Ag N-(pyridin-2-yl)pyridine-sulfonamide derivatives and their use in the treatment of disease

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5962490A (en) * 1987-09-25 1999-10-05 Texas Biotechnology Corporation Thienyl-, furyl- and pyrrolyl-sulfonamides and derivatives thereof that modulate the activity of endothelin
WO2002024665A1 (en) * 2000-09-25 2002-03-28 Actelion Pharmaceuticals Ltd Arylalkane-sulfonamides having endothelin-antagonist activity
US20020132836A1 (en) * 2000-10-11 2002-09-19 Chemocentryx Inc. Compounds and methods for modulating CCR4 function
EP1541563A4 (en) * 2002-07-10 2007-11-07 Ono Pharmaceutical Co ANTAGONIST OF CCR4 AND CORRESPONDING MEDICINAL USE
SE0301650D0 (sv) * 2003-06-04 2003-06-04 Astrazeneca Ab Novel compounds
SE0301653D0 (sv) * 2003-06-05 2003-06-05 Astrazeneca Ab Novel compounds

Also Published As

Publication number Publication date
US20060189613A1 (en) 2006-08-24
JP2006526619A (ja) 2006-11-24
EP1633723A1 (en) 2006-03-15
AR044613A1 (es) 2005-09-21
UY28345A1 (es) 2005-01-31
SA04250149A (ar) 2005-12-03
TW200509935A (en) 2005-03-16
WO2004108690A1 (en) 2004-12-16

Similar Documents

Publication Publication Date Title
NL301145I2 (nl) Tirbanibulin
TR200202194T2 (tr) Poliglütamik asit-kamptotesin birleşikleri ve hazırlama yöntemleri
ATE461217T1 (de) Glp-1-verbindungen
AU302959S (en) Toothbrush
DE60310576D1 (en) 2-hydroxy-6-phenylphenanthridine als pde-4-hemmer
IS7520A (is) Pyrimidínonefnasambönd, samsetningar og aðferðir
MXPA05011643A (es) 5,7-diaminopirazolo[4,3-d]pirimidinas en el tratamiento de hipertension.
NL1025068A1 (nl) Pyrrolopyrimidinederivaten.
MXPA03007140A (es) Derivados de carbolina.
DE602005011780D1 (de) Triazinderivate mit carbamatfunktion
DK1585737T3 (da) Uraciler med herbicid virkning
WO2007120333A3 (en) Tetracyclic kinase inhibitors
HK1083503A1 (en) Novel pyrimidine-4, 6-dicarboxamides for the selective inhibition of collagenases
SE0301654D0 (sv) Novel compounds
SE0301650D0 (sv) Novel compounds
EA200800223A1 (ru) ПРОИЗВОДНЫЕ ПИРИДО[2,3-d]ПИРИМИДИНА, ИХ ПОЛУЧЕНИЕ, ИХ ПРИМЕНЕНИЕ В ТЕРАПИИ
ATE509933T1 (de) Pentacyclische kinaseinhibitoren
NO20054053D0 (no) Triazolforbindelser anvendbare i terapi.
RS51138B (sr) S-mirtazapin za lečenje nastupa vreline (valunga)
IS7507A (is) Ný efnasambönd
NO20054064L (no) Slipemaskin.
DK1713438T3 (da) Medicinsk sæbe
WO2007076320A8 (en) Compounds
PL376130A1 (en) Controlled releases system containing temozolomide
DE602004013011D1 (de) Haarbehandlungszusammensetzungen